1 Introduction The expanded clinical spectrum of autoantibody-associated neurological diseases has identified many potentially treatable, and therefore “not to miss,” clinical phenotypes [1-3]. The associated increase in indiscriminate testing has resulted in frequent detection of clinically irrelevant antibodies, representing the commonest precipitant of misdiagnosis and iatrogenic harm in this field [4-6].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile